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ORIGINAL ARTICLE

Anti‐human CD9 antibody Fab fragment impairs the
internalization of extracellular vesicles and the nuclear transfer
of their cargo proteins
Mark F. Santos1 | Germana Rappa1 | Jana Karbanová2 | Cheryl Vanier1 |
Chikao Morimoto3 | Denis Corbeil2
1

| Aurelio Lorico1,4

College of Medicine, Touro University
Nevada, Henderson, Nevada

Abstract

2

The intercellular communication mediated by extracellular vesicles (EVs) has gained
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international interest during the last decade. Interfering with the mechanisms regu‐
lating this cellular process might find application particularly in oncology where can‐
cer cell‐derived EVs play a role in tumour microenvironment transformation. Although
several mechanisms were ascribed to explain the internalization of EVs, little is our
knowledge about the fate of their cargos, which are crucial to mediate their function.
We recently demonstrated a new intracellular pathway in which a fraction of endo‐
cytosed EV‐associated proteins is transported into the nucleoplasm of the host cell
via a subpopulation of late endosomes penetrating into the nucleoplasmic reticulum.
Silencing tetraspanin CD9 both in EVs and recipient cells strongly decreased the en‐
docytosis of EVs and abolished the nuclear transfer of their cargos. Here, we investi‐
gated whether monovalent Fab fragments derived from 5H9 anti‐CD9 monoclonal
antibody (referred hereafter as CD9 Fab) interfered with these cellular processes. To
monitor the intracellular transport of proteins, we used fluorescent EVs containing
CD9‐green fluorescent protein fusion protein and various melanoma cell lines and
bone marrow‐derived mesenchymal stromal cells as recipient cells. Interestingly,
CD9 Fab considerably reduced EV uptake and the nuclear transfer of their proteins
in all examined cells. In contrast, the divalent CD9 antibody stimulated both events.
By impeding intercellular communication in the tumour microenvironment, CD9 Fab‐
mediated inhibition of EV uptake, combined with direct targeting of cancerous cells
could lead to the development of novel anti‐melanoma therapeutic strategies.
KEYWORDS

cancer, CD9, endocytosis, extracellular vesicle, Fab fragment, nucleoplasm

1 | I NTRO D U C TI O N

contact or soluble molecules, but also by extracellular vesicles
(EVs), ie lipid bilayer‐enclosed nanobiological units actively re‐

Growing evidence indicate that intercellular communication in

leased from all cell types.1,2 In contrast to soluble signalling mol‐

multicellular organisms is mediated not only by direct cell‐cell

ecules, bioactive compounds associated with EVs (eg, proteins,

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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nucleic acids such as non‐coding RNA [including microRNA],
3,4

4409

the gene expression of the host cells. These surprising findings are

EVs

in line with numerous studies showing the atypical nuclear localiza‐

are found in internal and external bodily fluids and act as mediators

tion of the EV‐associated proteins CD9 and CD133 as well as the

of long‐distance transfer of biological information. Physiological

shuttling of proteins and nucleic acids to nucleoplasm of recipient

and pathological conditions determine the nature of EVs released

cells.3,24-28 Recently, we described that two proteins, ie vesicle‐as‐

by the producing cells as well as the abundance of their bioactive

sociated membrane protein‐associated protein A (VAP‐A) and the

cargo molecules. 5 Under physiological states, EVs can play import‐

cytoplasmic oxysterol‐binding protein‐related protein 3 (ORP3),

ant roles during embryonic development and afterward in the ho‐

are essential for the entry and the tethering of late endosomes to

moeostasis of various organ systems (reviewed in Ref. 6). In cancer,

nuclear envelope invaginations of type II (Figure 1B). They form a

they could promote pro‐angiogenic events and alter the surround‐

tripartite complex with late endosome‐associated Rab7 proteins. 29

ing cellular components as well as extracellular matrix to develop

Silencing VAP‐A or ORP3 abrogated the association of Rab7‐posi‐

the pre‐metastatic niche.7,8 With regard to clinical purposes, EVs

tive late endosomes with nuclear envelope invaginations, hence the

attract additional interest because their production is deregulated

transport of internalized EV‐derived cargo molecules to the nucle‐

in human diseases, notably in cancer; hence, their cargo molecules

oplasm of recipient cells. 29 The nuclear pores play a role in these

mRNA and genomic DNA) are protected from degradation.

9,10

can be monitored as biofluid‐associated markers.

Furthermore,

processes given the treatment with importazole, a small molecule in‐

EVs can be engineered for the selective therapeutic delivery of

hibitor of importin‐β‐mediated nuclear import, impaired the nuclear

biomacromolecules. 6,11

transfer of EV‐derived proteins. 23 Finally, the initial internalization

Two major general pathways were ascribed to explain the

of CD9+ EVs occurs by endocytosis, which is an essential step for

biogenesis and release of EVs by donor cells as exosomes or ec‐

the nuclear localization of EV‐associated materials, given dynasore

tosomes.12 The first class of EVs is derived from the internal intra‐

and methyl‐β‐cyclodextrin, two compounds known to inhibit the en‐

luminal vesicles of multivesicular bodies (MVBs) that are formed

docytosis mediated by clathrin/dynamin and lipid raft respectively,

by the inward budding of the endosomal membrane during the

abrogated it. 23

maturation of MVBs. Upon fusion with the plasma membrane,

CD9 (alias Tetraspanin‐29, motility‐related protein‐1) is an inte‐

MVBs release them outside the cell. The diameter of exosomes

gral membrane protein that is physiologically involved in cell fusion,

varies from 30 to 120 nm. Outward budding and fission of plasma

adhesion and motility.30-32 For instance, CD9 has an important role

membrane generate the second class of EV. Thus, ectosomes are

in muscle cell fusion and in canine distemper virus and HIV‐1‐induced

typically larger than exosomes and their diameter varies from

cell‐cell fusion.33-35 Depending on the context, CD9 functions have

100 nm to 1 μm. We have previously shown that ectosomes can

a metastasis suppressor or promoter activity (reviewed in Ref.36).

bud from microvilli and/or cilia.

Once released into the ex‐

CD9 has been extensively studied as a potential therapeutic target.

tracellular milieu, the uptake of EVs by recipient cells can be ac‐

Anti‐CD9 monoclonal antibodies (Ab) were found to specifically in‐

complished by several molecular mechanisms of internalization,

hibit the trans‐endothelial migration of melanoma cells.37 We have

13,14

15-18

which are not mutually exclusive,

such as clathrin‐mediated

shown that anti‐CD9, but not anti‐CD133, Ab enhances the nuclear

endocytosis17 or lipid raft‐dependent endocytosis.19 In spite of

uptake of EVs in recipient cells (Figure 1C). 23 This effect is greater in

this knowledge, fundamental questions remain about the fate of

melanoma cells than in mesenchymal stromal cells (MSCs), presum‐

endocytosed EVs particularly their biological cargo, which is cru‐

ably because of the higher expression level of CD9 in cancer cells in

cial for their function. 20

comparison to stromal cells. Moreover, silencing CD9 in EVs and/or

Our groups are studying EVs released by stem cells and cancer‐

recipient cells strongly decreased the endocytosis of EVs and abol‐

ous cells, notably melanoma cells. We have extensively character‐

ished the nuclear transfer of their contents, even in the presence of

ized those secreted by metastatic FEMX‐I cells. Electron microscopy

the anti‐CD9 Ab (Figure 1C). 23

examination has revealed the presence of a mixture of small and

Here, we designed a strategy to block the uptake of EVs and

large EVs, suggesting that exosomes and ectosomes are simulta‐

the nuclear translocation of their cargos by recipient cells. To that

neously produced. 21 The proteomic analysis of EVs, particularly

aim, we generated an antigen‐binding fragment (Fab fragment;

those harbouring the stem (cancer stem) cell marker CD133, 22 has

hereafter CD9 Fab) from 5H9 anti‐CD9 Ab (CD9 Ab), which could

defined their contents. They are particularly rich in tetraspanin pro‐

potentially saturate CD9 molecules present at the cell surface of

teins (CD9, CD63 and CD81) and in pro‐metastatic proteins, notably

host cells and EV‐associated ones and hence impair their func‐

CD44, MAPK4K, ADAM10 and Annexin A2. Importin β1, a protein

tion. 38 The Ab and Fab fragment derived therefrom have been

mediating nuclear transportation of cytoplasmic proteins through

successfully employed for the treatment of different types of

the nuclear pore complex, was also found therein. By monitoring the

cancer, mainly through the inhibition of cell surface receptors. 39

internalization of melanoma‐derived EVs and the intracellular routes

We report that monovalent CD9 Fab at doses achievable in vivo 40

of their content, particularly CD9 (see below), we discovered that

impedes the uptake of EVs in different melanoma cell lines and

EV‐associated proteins are transported into the nucleus of the host

primary MSCs and consequently inhibits the nuclear transfer of

cell through late endosomes entering the nucleoplasmic reticulum

their cargo proteins. Combined with other approaches, notably

(Figure 1A). 23 Therein, EV‐associated cargo molecules can modify

the direct targeting of cancer cells, such setting could lead to a

4410
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new modality in cancer treatment by inhibiting the intercellular

absorbance at 280 nm. Aliquots of the antibody (1 mg/mL) were stored

communication within the cancer cell niche.

at −80°C without addition of sodium azide.
The Fab fragment was generated using the Pierce Fab Purification
kit (#44985; Thermo Fisher Scientific). Briefly, the CD9 Ab (500 μg)

2 | M E TH O DS

was incubated with papain immobilized on agarose resin for 3 hours at
37°C. The digested antibody was collected by centrifugation (5000 g,

2.1 | Cell culture

1 minute) using a spin column and the flow through containing the an‐

The FEMX‐I cell line was originally derived from the lymph node me‐

tibody was placed in a new tube. The column was then washed once

tastasis of a patient with malignant melanoma.41 FEMX‐I cells were

with PBS to recover any remaining antibody, which was pooled with

41,42

They were found to be

the flow through. The fragment crystalline (Fc) fragment was then re‐

wild‐type for BRAF, PTEN and NRAS.23,29 The human A375 melanoma

highly metastatic in immunodeficient mice.

moved from digested antibody samples using NAb Protein A Plus Spin

cell line was obtained from the American Type Culture Collection (cat‐

Column. After 10 minutes of centrifugation (1000 g), the Fab fragment

alog number #CRL‐1619™), whereas the human C8161 melanoma cell

found in the flow through was collected. The column was then washed

line was obtained from G. Pizzorno (University of Tennessee College

twice with PBS. Each washing fraction was pooled with the Fab frac‐

of Medicine, Chattanooga, TN).43,44 All cell lines were cultured in

tion. Antibody was concentrated using Microsep™ Advance Centrifugal

RPMI‐1640 (#10‐041‐CV; Corning Inc., Corning, NY) containing 10%

Devices (10K molecular weight cut‐off; Pall Corporation). The final

foetal bovine serum (FBS; Atlanta Biologicals Inc., Flowery Branch,

concentration of CD9 Fab was 0.75‐0.85 mg/mL. The Fab preparation

GA), 2 mmol/L l‐glutamine, 100 U/mL penicillin and 100 μg/mL strep‐

was assessed using sodium dodecyl sulphate‐polyacrylamide gel elec‐

tomycin (Corning Inc.). Cells were used between passages 3 and 15.

trophoresis (SDS‐PAGE) and Coomassie blue staining (see below).

Cell lines were authenticated by morphology, proteomics and gene
expression analysis as described.45 They were regularly tested for my‐
coplasma contamination using Venor™ GeM mycoplasma detection kit
(Sigma‐Aldrich, St. Louis, MO).

2.3 | SDS‐PAGE and immunoblotting
Preparation of Fab fragments was assessed using SDS‐PAGE under

Human bone marrow‐derived MSCs, isolated from bone marrow

non‐reduced or reduced (ie in the presence of β‐mercaptoetha‐

aspirates from normal adult donors after obtaining informed consent

nol) conditions. Samples were run on a 4%‐12% Bis‐Tris precast

as described,

46

were obtained from Dr. D. J. Prockop (Texas A&M) and

gel (Thermo Fisher Scientific, Life Technologies) and stained with

prepared under a protocol approved by the Texas A&M Institutional

Coomassie blue (Teknova, Hollister, CA) for 10 minutes. The gel was

Review Board. MSCs were used between passages 2 and 5. Their

destained with 40% methanol/10% acetic acid solution.

multipotency was regularly monitored by their differentiation into
adipocytes and osteoblasts.

47

Cells were solubilized in lysis buffer (1% Triton X‐100,

MSCs and FEMX‐I cells expressing ec‐

100 mmol/L NaCl, 50 mmol/L Tris‐HCl, pH 7.5) supplemented with

topically CD9‐green fluorescent protein (GFP) fusion protein were

the Set III protease inhibitor cocktail (Calbiochem, Burlington, MA)

established as described. 23 Under these conditions, almost all cells

for 30 minutes on ice. Cell lysates were centrifuged at 12 000 g

are positive. They were used to produce fluorescent EVs (see below).

for 10 minutes in 4°C. The supernatant was collected and Laemmli

FEMX‐I cells depleted of CD9 by means of CD9 shRNA lentiviral par‐

sample buffer without reducing agent was added. Proteins were

ticles were previously described. 23 Approximately 85% of infected

separated using either 12% SDS‐PAGE gel (Figure 2 and Figure

cells showed no CD9 expression (data not shown).

S1) or a precast gel (see above; Figure S3) along with the Trident
prestained protein molecular weight ladder (GeneTex, Irvine, CA)

2.2 | Production of CD9 antibody Fab fragment

and transferred overnight at 4°C to a nitrocellulose membrane

Culture of 5H9 hybridoma cells38 and the production of CD9 Ab were

brane (Millipore, Bedford, MA: pore size 0.45 μm). After transfer,

performed at Mayo Clinic (Antibody Hybridoma Core, Rochester, MN).

membranes were incubated in a blocking buffer (PBS contain‐

Conditioned media from hybridoma cultures growing in roller bottles in

ing 1% bovine serum albumin [BSA] or 5% low fat milk powder

IMDM media (#12440‐053, Thermo Fisher Scientific, Gibco, Waltham,

and 0.3% Tween 20) for 60 minutes at room temperature (RT).

MA) containing 10% premium FBS (#S11150, Atlanta Biologicals Inc.,

Afterward, the membranes were probed using either primary

Flowery Branch, GA) was pelleted in 250 mL centrifuge tubes at 1600 g

CD9 Fab (1 μg/mL) generated from mouse 5H9 Ab (see above)

(Thermo Fisher Scientific) or poly(vinylidene difluoride) mem‐

The supernatant was clarified through 0.45‐μm Nalgene filters to re‐

or commercial mouse anti‐CD9 (clone P1/33/2, #sc‐20048;

move remaining cell debris. The clarified supernatant was then passed

Santa Cruz Biotechnology, Santa Cruz, CA) or anti‐β‐actin (clone

through and bound to Protein G Sepharose FF HiLoad™ 26/40 columns

C4, #sc‐47778; Santa Cruz Biotechnology) Ab for 60 minutes at

(GE Healthcare, Pittsburgh, PA). Bound antibody was eluted with

RT. After three washing steps of 10 minutes each with PBS con‐

100 mmol/L glycine buffer, pH 2.7. Eluted Ab was then immediately

taining 0.1% Tween 20, the antigen‐antibody complexes were

neutralized with 1 mol/L Tris‐HCl, pH 9 and desalted with HiPrep

detected using two protocols. In the case of CD9 Fab, we used

26/10 columns (GE Healthcare). The buffer was exchanged with 1X

goat anti‐mouse Fab specific horseradish peroxidase (HRP)‐con‐

PBS and the protein concentration was determined by measuring

jugated secondary antibody (#A2304; Sigma‐Aldrich), which was

|
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visualized with enhanced chemiluminescence reagents (ECL sys‐

prior to fixation. EVs were derived from the same cell type as used

tem; Amersham Corp., Arlington Heights, IL). The membranes

for the recipients except for A375 and C8161 cells in which EVs were

were exposed to films (Hyperfilm ECL; Amersham‐Pharmacia).

produced from CD9‐GFP transfected FEMX‐I cells. In some experi‐

With other Abs, the IRDye 680RD anti‐mouse IgG (#926‐68070;

ments, EVs and/or cells were pre‐incubated with CD9 Fab or CD9 Ab

LI‐COR Biosciences, Lincoln, NE) was applied. Membranes were

at various concentrations as indicated for 30 minutes at 4 and 37°C

washed thrice (10 minutes each) in PBS containing 0.1% Tween 20,

respectively. The EVs and cells were then incubated together in the

rinsed in ddH2O and antigen‐antibody complexes were visualized

presence of antibodies (or without as control) for 5 hours at 37°C

using an Odyssey CLx system (LI‐COR).

prior to analysis.

2.4 | Production of CD9‐GFP+ EVs

2.6 | Confocal laser scanning microscopy and
fluorescence quantification

Extracellular vesicles were enriched by differential centrifugation
from 72 hour‐conditioned media (serum‐free Dulbecco's modified

Cell surface immunolabelling of native or CD9‐depleted FEMX‐I

eagle medium [DMEM]/Ham's F‐12 1:1, supplemented with 2% B‐27

cells was performed as described.48 Briefly, cells growing on fi‐

[Thermo Fisher Scientific]) of engineered FEMX‐I cells and MSCs

bronectin‐coated coverslips were washed with ice‐cold PBS con‐

expressing CD9‐GFP as described previously. 21,22 Conditioned me‐

taining 1 mmol/L CaCl2 and 0.5 mmol/L MgCl2 (Ca/Mg‐PBS) and

dium was centrifuged at 10 000 g for 30 minutes at 4°C and the re‐

incubated in blocking buffer I (Ca/Mg‐PBS containing 0.2% gela‐

sulting supernatant was centrifuged at 200 000 g for 60 minutes at

tin) for 10 minutes. Cells were then incubated for 30 minutes with

4°C. The pellet was re‐suspended in 200 μL of PBS. To determine

CD9 Fab or CD9 Ab at different concentrations (eg, 5, 10, 25 and

the EV concentration, we used the light‐scattering characteristics

50 μg/mL) diluted in blocking buffer. The whole procedure was

of 488‐nm laser light on EV preparations undergoing Brownian

performed at 4°C. Afterward, they were fixed in 4% paraformalde‐

motion injected by continuous flow into the sample chamber of a

hyde (PFA) for 30 minutes at RT, quenched with 50 mmol/L NH4Cl

Nanosight LM10 unit (Malvern Panalytical Inc., Westborough, MA).

for 10 minutes, washed in PBS and incubated in blocking buffer II

The calculated EV concentration was an average of six 30‐second

(PBS containing 0.2% gelatin) for 20 minutes. Samples were incu‐

video recordings. As described previously, the average size of EVs

bated with fluorescein isothiocyanate (FITC)‐conjugated secondary

produced by FEMX‐I cells and MSCs was 123 and 114 nm respec‐

antibody specific either for the mouse Fab or Fc fragment (#F4018,

tively. 23 Those produced by FEMX‐I cells were formerly character‐

#F5387 respectively, 1:200; Sigma‐Aldrich) diluted in blocking

ized by electron microscopy. 21

buffer II. Nuclei were labelled with 4′‐6‐diamidino‐2‐phenylindole
(1 μg/mL; Sigma‐Aldrich). Cells were washed with PBS and distilled

2.5 | Incubation of cells with EVs

water then mounted in Mowiol 4.88 (Merck, Darmstadt, Germany).
Images were captured with Leica SP5 upright confocal microscope

Cells (1 × 105) were plated into 35‐mm microscopy dishes containing

under the same settings for both Fab‐ and Fc‐specific secondary

0.17‐mm thick glass coverslips on the bottom and incubated over‐

antibody labelling. Composites of 27‐30 optical sections are shown

night at 37°C to allow complete cell adherence (MatTek Corporation,

(Figure 2A,B). The images were prepared using Fiji49 and Adobe

Ashland, MA). Afterward, they were incubated with various concen‐

Illustrator software.

trations of CD9‐GFP+ EVs (eg, 5 × 107 particles per mL [0.075 μg pro‐

Alternatively, cells incubated with CD9‐GFP+ EVs (see above)

tein per mL]; 2.5 × 10 particles per mL [0.375 μg protein per mL] or

were fixed in 4% PFA and afterward permeabilized with 0.2%

1 × 10 particles per mL [1.5 μg protein per mL]) for 5 hours at 37°C

Tween 20 diluted in PBS (permeabilization buffer). Both steps

8

9

F I G U R E 1 Entry and delivery of extracellular vesicles (EV)‐derived cargo molecules into the nucleoplasm of recipient cells. A, Two
major steps were proposed to explain the delivery of EV‐associated molecules to the nuclear compartment of recipient cells. First, the
EVs are internalized by endocytosis at the plasma membrane (i). Second, once inside the endocytic pathway, a fraction of late endosomes
(LE) penetrates the type II nuclear envelope invaginations where their content, notably the endocytosed EV‐associated molecules, are
transferred into the nucleoplasm (ii). Two types of nuclear envelope invaginations are described. Type I invaginations (I) are those in which
solely the inner nuclear membrane (INM) penetrates into the nucleoplasm, whereas type II invaginations (II) involve both the outer nuclear
membrane (ONM) and INM. The endoplasmic reticulum (ER) is a continuation of ONM. B, Key players involved in the translocation of Rab7+
late endosomes to nuclear envelope invagination. Two proteins, vesicle‐associated membrane protein‐associated protein A (VAP‐A) and the
cytoplasmic oxysterol‐binding protein‐related protein 3 (ORP3) forming a tripartite complex with late endosome‐associated Rab7 protein,
are indispensable for the entry of late endosomes to the nuclear envelope invagination and/or their tether to ONM (I). Nuclear pores are
somehow involved in the translocation of EV‐associated soluble (II) and membranous (III) cargo molecules into the nucleus. It remains to
be explained how membranous components of EVs are extracted from the late endosomal membrane upon fusion of the former with
the latter and the transport mechanism through nuclear pores, which are size restricted. C, Silencing CD9 in recipient cells and/or EVs or
both interferes with the endocytosis of EVs and the nuclear transfer of their cargo molecules. Although the presence of divalent CD9 Ab
stimulated these events with native cells and EVs, the lack of CD9 abrogated them. 23 Panels A and B were modified from Ref. 29
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were performed for 15 minutes at RT. They were then incubated in

diluted in permeabilization buffer containing 1% BSA. Cells were

blocking buffer III (PBS containing 1% BSA) and labelled with mouse

imaged in PBS using confocal laser scanning microscopy (CLSM)

anti‐SUN2 Ab (clone A‐10, #sc‐515330; Santa Cruz Biotechnology)

using a Nikon A1R+ inverted confocal microscope with a 60X Apo‐

for 60 minutes each step at RT. Cells were washed twice with

TIRF oil‐immersion objective and a numerical aperture of 1.49 at

PBS, incubated with tetramethylrhodamine (TRITC)‐conjugated

either 512 × 512 or 1024 × 1024 pixel resolution. Solid‐state la‐

anti‐mouse IgG (#715‐025‐150; Jackson ImmunoResearch, West

sers of 488, 561 and 638 nm solid‐state lasers were used to excite

Grove, PA) or Cy5‐conjugated anti‐mouse IgG (#715‐175‐150;

GFP, TRITC and Cy5 respectively and corresponding fluorescence

Jackson ImmunoResearch) secondary antibodies for 30 minutes

emissions were collected using 500‐550, 570‐620 and 662‐737 nm

and again washed twice prior to observation. All antibodies were

long pass filters.

|
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F I G U R E 2 Characterization of CD9 Fab. A, Cell surface
immunofluorescence on native FEMX‐I cells. FEMX‐I cells
were surface labelled in the cold with CD9 Fab at different
concentrations as indicated (μg/mL), PFA‐fixed and incubated
with either anti‐Fab (top panels) or anti‐Fc (bottom panels)
specific secondary conjugated to a fluorochrome (green). Nuclei
were counterstained with 4′‐6‐diamidino‐2‐phenylindole (DAPI).
B, Cell surface immunofluorescence on CD9‐depleted FEMX‐I
cells. Native FEMX‐I cells and CD9 shRNA‐transduced cells were
surface‐labelled in the cold with CD9 Fab (top panels) or CD9 Ab
(bottom panels) at different concentrations (μg/mL), as indicated,
PFA‐fixed and incubated with anti‐Fab or anti‐Fc specific secondary
conjugated to a fluorochrome (green) respectively, prior to
DAPI staining. Note that under these conditions, about 15% of
infected cells still express CD9 in a proportion similar to native
cells (asterisks). Scale bar, 25 μm. C, Immunoblotting. Detergent
cell lysate (100‐μg protein) prepared from melanoma FEMX‐I
cells was probed using Fab CD9 and horseradish peroxidase‐
coupled anti‐Fab specific secondary antibody. β‐actin was used
as control. Position of prestained molecular weight markers (kDa)
are indicated. Bracket, CD9 immunoreactivity. D, Flow cytometry.
FEMX‐I cells were surface labelled with either CD9 Fab (10 μg/
mL, top) or CD9 Ab (10 μg/mL, bottom) followed by fluorochrome‐
conjugated anti‐Fab or anti‐Fc specific secondary antibody
respectively. E, CD9 Fab inhibits the cell binding of native CD9 Ab.
FEMX‐I cells were sequentially labelled with CD9 Fab at different
concentrations as indicated (μg/mL) followed by CD9 Ab (10 μg/
mL) and fluorochrome‐conjugated anti‐Fc specific secondary
antibody. Samples were analysed using flow cytometry. The
median fluorescence intensity (MFI) is indicated. As negative and
background controls, primary Ab (D) or CD9 Ab (E) was omitted

2.7 | Flow cytometry
FEMX‐I cells were trypsinized using 0.05% trypsin with 0.53 mmol/L
EDTA (Corning Inc.), washed twice in PBS and re‐suspended in PBS
containing 1% BSA. Cell suspension aliquots of 100 μL (1 × 10 6
cells) were incubated with either CD9 Fab or CD9 Ab (clone 5H9)
(both at 10 μg/mL in PBS containing 1% BSA) for 30 minutes at 4°C.
After two washing steps with PBS, samples were incubated with
FITC‐conjugated secondary antibody specific either for the mouse
Fab or Fc fragment (see above, 1:600) for another 30 minutes at
All images were acquired under the same microscope settings

4°C. As negative controls, primary Ab was omitted. For competi‐

for subsequent calculations of mean fluorescence intensity and

tive inhibition experiment, cells were incubated first with CD9 Fab

recorded using NIS Elements software (Nikon). Raw images were

at different concentrations (0, 5, 10, 25 and 50 μg/mL) and then

processed using Fiji. Each optical section through the cell (21 sec‐

with CD9 Ab (10 μg/mL) followed by Fc‐specific FITC‐conjugated

tions of 0.4 μm for cancer cells and 0.2 μm for MSCs) was assessed

secondary antibodies. All incubations were performed for 30 min‐

individually. Any observed GFP fluorescent signal was counted as

utes at 4°C. To set up the background staining reminiscent of a

EV‐derived biomaterials and data collectively calculated. To count

residual undigested CD9 Ab in CD9 Fab preparation, we omitted

nuclear fluorescent materials, a region of interest (ROI) was drawn

CD9 Ab. After washing with PBS, 20 000 events were acquired on

along the nucleus on each optical section and an auto threshold

a LSRII flow cytometer (BD Biosciences). Instrument settings and

generated by Fiji was applied. Positive signals were counted using

gating strategies were established using cells incubated solely with

the “analyze particle” function. To determine the value of cyto‐

individual secondary antibody as negative controls. Data were

plasmic GFP fluorescence for each cell, an ROI was also drawn

analysed using FlowJo software (TreeStar, Ashland, USA). Median

around the cytoplasm, using the cell border as a guide, but exclud‐

fluorescence intensity (MFI) was calculated as a difference of MFI

ing the nucleus.

values of stained and negative control populations.

4414
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To determine the amount of cell surface CD9 molecules in a given
™

cell, Quantum Simply Cellular

®

top panels). In contrast, solely a very weak labelling was detected

anti‐mouse IgG kit (#815; Bangs

with a secondary antibody directed against mouse Fc, indicat‐

Laboratories Inc., Fishers, IN) was utilized. Cells (1 × 105) and 4 mi‐

ing the effective papain digestion of CD9 Ab (Figure 2A, bottom

crosphere populations, containing increasing levels of Fc‐specific

panels). When a similar experiment was performed with CD9‐de‐

capture antibody, were incubated with phycoerythrin‐conjugated

pleted FEMX‐I cells, 23 almost no immunolabelling was detected

anti‐CD9 Ab (clone M‐L13, #555372; BD Biosciences, San Jose, CA)

either with CD9 Fab or full‐length antibody (Figure 2B, top and

in PBS containing 0.5% BSA for 30 minutes on ice. Both cells and

bottom panels respectively). Second, we analysed whether CD9

microspheres were then analysed using flow cytometry using the

Fab can recognize CD9 by immunoblotting. To that end, deter‐

same settings as above according to manufacturer's instructions. A

gent lysate prepared from FEMX‐I cells was resolved on SDS‐

standard curve was generated using the median channel values of

PAGE under non‐denaturing condition and probed with CD9 Fab.

the microspheres and the amount of CD9 molecules per cell was de‐

As shown in Figure 2C, CD9 Fab recognized the CD9 molecules.

termined from this curve. All calculations were performed with the

Third, we evaluated the capacity of CD9 Fab to detect its antigen

QuickCal analysis program provided in the kit.

using flow cytometry. A suspension of FEMX‐I cells was subjected
to immunolabelling in the cold using either CD9 Fab or full CD9

2.8 | Statistical analysis

Ab followed by fluorochrome‐conjugated secondary antibody
specific either for mouse Fab or Fc fragment respectively. As

All experiments were performed at least in triplicate. A minimum

negative control, primary antibody was omitted. Flow cytometry

of 30 cells was analysed in each experiment. Error bars in graphical

analyses indicated that CD9 Fab could detect CD9+ cells similar to

data represent means ± standard deviation. Statistical analysis was

the native anti‐CD9 Ab (Figure 2D). Altogether, these experiments

determined by one‐way analysis of variance followed by pairwise

demonstrated that CD9 Fab recognizes its antigen under various

comparison of means with Dunnett's multiple comparison adjust‐

conditions, notably its native conformation.

ment using the statistical program Stata 12 (StataCorp LLC, College
Station, TX). P‐values inferior to 0.05 were considered significant.

3 | R E S U LT S

3.3 | CD9 Fab interferes with the cell binding of
native CD9 antibody
Can CD9 Fab interfere with the binding of corresponding native CD9

3.1 | Generation of CD9 antibody Fab fragment
Given the positive impact of divalent Ab directed against CD9
+

Ab? To address this issue, we pre‐incubated FEMX‐I cells in suspen‐
sion with various concentrations of CD9 Fab prior to the addition of
CD9 Ab and fluorochrome‐conjugated secondary antibody specific

on the uptake of CD9 EVs by melanoma cells and the negative

for the Fc fragment. Samples were analysed by flow cytometry. As a

impact upon silencing CD9 on either EVs or recipient cells, 23 we

positive control, CD9 Fab was omitted whereas CD9 Ab was absent

sought whether CD9 Fab could influence the internalization and

for the background control. As shown in Figure 2E, CD9 Fab blocked

consequently the intercellular transfer of EV‐associated cargo

the binding of the native Ab in a dose‐dependent fashion, indicating

molecules. To investigate this issue, we generated CD9 Fab from

that it could specifically label the cell surface CD9 molecules. We

5H9 Ab, which recognizes an unidentified epitope in the extracel‐

concluded that the monovalent CD9 Fab could be useful in achieving

lular part of CD9 (Figure S1A). 38 The Ab (IgG1 kappa) produced

our objective, ie interfering with the uptake of CD9+ EVs.

from hybridoma clone 5H9 was digested with papain to generate
the Fab and Fc fragments. The latter were removed selectively
using immobilized protein A (Figure S1B). As observed using SDS‐
PAGE under non‐reducing and reducing conditions, the 5H9 Ab

3.4 | Differential effect of CD9 Fab versus native
antibody on the internalization of EVs

was successfully digested and the 50‐kDa CD9 Fab was isolated

To determine the impact of CD9 Fab on the internalization of EVs

(Figure S1C).

by melanoma cells, we used engineered FEMX‐I cells to express the
CD9‐GFP fusion protein.23 These cells release in vivo‐labelled fluo‐

3.2 | Characterization of CD9 Fab

rescent EVs that could be used to monitor EV uptake upon incuba‐
tion with recipient cells. CD9‐GFP+ EVs released in the conditioned

To determine the functionality of CD9 Fab, we evaluated its bind‐

culture media were enriched by differential centrifugation (for details

ing to melanoma FEMX‐I cells by various methods. First, cells

see Methods,23). Prior to the exposure of native FEMX‐I cells to CD9‐

growing on fibronectin‐coated support were surface labelled in

GFP+ EVs, cells were pre‐incubated for 30 minutes at 37°C with either

the cold with CD9 Fab at different concentrations followed by a

CD9 Fab or CD9 Ab (25 μg/mL). As control, no antibody was added.

fluorochrome‐conjugated secondary antibody specific either for

Afterward, cells were incubated with CD9‐GFP+ EVs (2.5 × 108 parti‐

the mouse Fab or Fc fragment. The CLSM analysis revealed that

cle per mL) without removing the antibodies for 5 hours and then fixed,

the antigen‐CD9 Fab complex is recognized by anti‐Fab secondary

immunolabelled for protein SUN domain‐containing protein 2 (SUN2),

antibody already at low concentration of primary Ab (Figure 2A,

an inner nuclear membrane protein and analysed using CLSM. At first

SANTOS et al.
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glance, we noticed that the uptake of CD9‐GFP+ EVs by recipient cells

was considerably reduced in the presence of CD9 Fab by compari‐

seemed variable under the native conditions, ie without the addition

son to control (Figure 3A, uncut)—for an overview see Figure S2A.

of CD9 Ab. Therein, GFP fluorescence appears as strong, medium or

Quantification of each optical section confirmed it (Figure 3B). In

weak among cells (Figure S2A). In contrast, GFP fluorescence becomes

contrast, the presence of CD9 Ab yielded the opposite effect, ie, an

more homogeneous within the cell population upon the addition of

increase of cytoplasmic CD9‐GFP was detected (Figure 3A, uncut;

antibodies. A three‐dimensional reconstruction of labelled recipient

3B). Interestingly, similar outcome were observed with two other

cell revealed that CD9‐GFP signal associated with their cytoplasm

melanoma cell lines, A375 and C8161, exposed to FEMX‐I cell‐derived

F I G U R E 3 CD9 Fab impedes the uptake of extracellular vesicles (EVs) and nuclear transfer of their cargo proteins in melanoma and
stromal cells. A‐C, FEMX‐I cells were pre‐incubated (30 min) without (control) or with CD9 Fab or CD9 Ab (25 μg/mL) prior to the exposure
to fluorescent EVs derived from CD9‐GFP+ FEMX‐I cells for 5 h. Different concentrations of EVs were used (A‐C, 2.5 × 10 8 particle per mL
[blue]; C, 5.0 × 107 [red] or 1.0 × 109 particle per mL [green]). Samples were then fixed and immunolabelled for SUN2 prior to confocal laser
scanning microscopy. A three‐dimensional reconstruction of the entire cell (uncut) or three sections (0.4‐μm slices each, section) is shown
(A). CD9‐GFP appears as discrete punctate signals either in the cytoplasm or nucleoplasm (circles) of recipient cells. The amount of CD9‐GFP
signal was quantified using serial optical sections through a cell using the cytoplasmic (B) and nuclear (C) compartments as a region of
interest (see Figure S2B). Mean with the range of fluorescence per slice from 10 individual cells are shown (B). D, Native MSCs were exposed
to EVs (1.0 × 109 particle per mL) derived from CD9‐GFP+ MSCs upon their pre‐incubation without or with CD9 Fab or CD9 Ab as described
above. Punctate nuclear CD9‐GFP signal per cell was quantified. Means ± SD are shown (C, D). 50 (C) or 20 (D) cells were evaluated per
experiment (n = 3). P‐values are indicated. N.S., not significant. Scale bars, 5 μm
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F I G U R E 4 CD9 Fab impedes the
uptake of extracellular vesicles (EVs)
and nuclear transfer of their cargo
proteins in various malignant melanoma
cells. (A‐C) Melanoma A375 or C8161
cells were incubated (30 min) without
(control) or with CD9 Fab or CD9 Ab
(25 μg/mL) prior to the exposure to
fluorescent EVs (2.5 × 10 8 particle per
mL) derived from FEMX‐I cells expressing
CD9‐GFP for 5 h. Samples were then
fixed and immunolabelled for SUN2 prior
to confocal laser scanning microscopy.
Cytoplasmic (A) and nuclear (B, C)
CD9‐GFP signals per cell were quantified
using Fiji. Means with the range of
fluorescence per slice from 10 individual
and representative cells are shown (A).
30 cells were evaluated per condition and
experiment (B) and the means ± SD of
three independent experiments are shown
(C). P‐values are indicated

CD9‐GFP+ EVs (Figure 4A), indicating that CD9 Fab inhibits the uptake

divalent Abs prior to incubation with CD9‐GFP+ EVs (2.5 × 10 8 par‐

of EVs.

ticle per mL) showed a decrease or an increase in the CD9‐GFP+
signals in the nucleoplasm respectively, compared to the control

3.5 | CD9 Fab inhibits the nuclear transfer of EV‐
derived cargo proteins
We previously reported that cargo proteins derived from EVs are

(Figure 3A, section, green circle; 3C; see also Table 1). As previ‐
ously demonstrated, 23,29 CD9‐GFP+ signal in the nuclear compart‐
ment appeared with a punctate pattern (Figure 3A; Figure S2B,
green circle).

not only internalized by host cells, but also a fraction of them is

The addition of different amounts of CD9‐GFP+ EVs (eg, 5.0 × 107

transferred to their nucleoplasm by the intermediate of late en‐

or 1.0 × 109 particle per mL) was also evaluated in FEMX‐I cells. In most

dosomes entering into nucleoplasmic reticulum.

23,29

Does CD9

cases, the numbers of nuclear CD9‐GFP were significantly lower or

Fab interfere with this mechanism? The analysis of the nuclear

higher in cells exposed to CD9 Fab or CD9 Ab respectively (Figure 3C).

compartment of melanoma cells pre‐treated with monovalent or

Only with a high amount of EVs (ie 1.0 × 109 particle per mL) no

|
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TA B L E 1 Differential impact of CD9
antibody on the nuclear localization of
extracellular vesicles (EV)‐derived cargo
protein

Antibody

Experimental
procedurea

Controlb

A

CD9 Fab

CD9 Ab

Average nuclear EV‐derived
CD9‐GFP per cellc

P‐values
(relative to
control)

8.42 ± 0.74

—

B

8.41 ± 0.61

—

C

8.02 ± 0.44

—

A

2.89 ± 0.13

0.05

B

2.99 ± 0.45

0.001

C

1.53 ± 0.09

0.0001

A

15.67 ± 1.20

0.005

B

14.17 ± 0.76

0.001

C

14.20 ± 0.32

0.0001

4417

P‐values (relative
to procedure A)

0.05

0.5

a

A, Cells were pre‐incubated with antibody (25 μg/mL, 30 min, 37°C) before the addition of
CD9‐GFP+EVs (5 h). B, CD9‐GFP+EVs were pre‐incubated with antibody (25 μg/mL, 30 min, 4°C)
before their incubation with cells (5 h). C, Cells and CD9‐GFP+EVs were pre‐incubated with
antibody (12.5 μg/mL each, 30 min, 37 or 4°C respectively) before their co‐culture (5 h).
b
Control refers to the three experimental procedures (A‐C) without the addition of antibody.
c
At least 30 cells were evaluated per condition (n = 3).

significant difference was observed between CD9 Ab and control. Similar
observations were made with A375 and C8161 cells (Figure 4B,C).
When the same experiments were performed with primary
MSCs as recipient cells as well as donor cells for fluorescent EVs
(1 × 109 particle per mL), we observed also a significant decrease
in nuclear and cytoplasmic CD9‐GFP in cells pre‐treated with CD9
Fab (25 μg/mL) (Figure 3D; data not shown). The CD9 Ab did not
significantly increase the EV uptake which can be explained by a lim‐
ited quantity of CD9 molecules in MSCs in comparison to melanoma
cells, as observed by immunoblotting and quantitative fluorescence
analyses using flow cytometry (Figure S3A‐C).

3.6 | A minimal concentration of CD9 Fab is
necessary to interfere with EV uptake
We assessed whether the uptake of EVs is dependent on the con‐
centration of CD9 Fab. FEMX‐I cells were subjected to increasing
concentrations of CD9 Fab or CD9 Ab prior to incubation with CD9‐
GFP+ EVs (2.5 × 10 8 particle per mL). As shown in Figure 5A, the up‐
take of EVs was progressively inhibited as the concentration of CD9
Fab increased, whereas the opposite effect was again observed in
cells treated with CD9 Ab, ie more EVs were internalized with in‐
creasing CD9 Ab concentration. A similar trend was observed in the
number of CD9‐GFP signals in the nuclear compartment (Figure 5B).
These results are in line with the interference of CD9 Fab to cell
surface CD9 Ab binding observed using flow cytometry (Figure 2E).
Thus, a minimal amount of antibody (ie 25 μg/mL) seems to be indis‐
pensable to inhibit (or promote) the EV uptake.
Lastly, we determined whether the pre‐incubation of EVs with
Ab (25 μg/mL) or of both EVs and cells individually, instead of cells

F I G U R E 5 Dose‐dependent inhibition of CD9 Fab on the
extracellular vesicles (EV) uptake and nuclear transfer of their cargo
proteins. (A, B) FEMX‐I cells were pre‐incubated (30 min) with
different concentration of CD9 Fab or CD9 Ab as indicated prior to
the exposure to CD9‐GFP+ EVs (2.5 × 10 8 particles per mL) for 5 h.
As control, no antibody was added (–). Cytoplasmic (A) and nuclear
(B) CD9‐GFP signals per cell were quantified using Fiji. Means ± SD
are shown. 10 (A) or 30 (B) cells were evaluated per experiment
(n = 3). They were evaluated in comparison to the control (A, red
line; B, –). ***, P ≤ 0.001. N.S., not significant
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only as performed until now, influenced internalization and the nu‐

individually with CD9 Fab is consistent with this scenario. Our data

clear localization of EV‐derived cargo proteins. We wanted to rule

are in line with an elegant study showing the CD9 Fab can inhibit the

out a potential negative impact of the addition of the Abs (CD9 Fab

transfer of materials between CD9‐containing membranous vesicles,

or CD9 Ab) to recipient cells, which could stimulate the internal‐

called epididymosomes and maturing epididymal spermatozoa.50 In

ization of cell surface CD9, hence limit the EV uptake. If it turned

contrast, divalent CD9 Ab promotes these events, which can be cor‐

out to be the case, all acquired numbers would be underestimated.

related to antibody‐induced cross‐linking of CD9 associated with EVs

Similarly, we wished to exclude that the addition of Abs, particularly

and host cells (Figure 6B). Does CD9 play a role in the initial adhe‐

CD9 Ab, to EVs would reduce their internalization by favouring, for

sion of EVs to the recipient cell? The earlier observation made with

instance, their clustering. As presented in Table 1, we found that the

sperm‐egg fusion suggests it. Jégou and colleagues demonstrated

pre‐incubation of cells with Abs did not influence the final outcome

that the fertilization process is controlled by sperm‐egg adhesion

when compared to the pre‐incubation of EVs (procedure A vs. B).

properties driven by CD9.51 In such process, CD9 might organize

However, the nuclear localization of EV‐derived cargo proteins was

the components (proteins and lipids) of plasma membrane and/or EV

significantly reduced when both entities (EVs and cells) were pre‐in‐

membrane into a specific tetraspanin web (Figure 6B, green), whose

cubated individually with the monovalent, but not the divalent, Ab

constituents (eg, adhesion proteins) would somehow regulate the in‐

(see procedure C by comparison to A).

teraction with EVs and promote their endocytosis.52-55 Similarly, CD9
has been proposed to act as a scaffold in the regulation of adhesion

4 | D I S CU S S I O N

molecules at the immune synapse and T lymphocyte activation.56 It
remains to be determined whether the cis‐dimerization of CD9 in the
membrane of recipient cells as well as in EVs is involved.57 We could

In this study, we demonstrated that a monovalent Ab directed against

not exclude that a trans‐dimerization of CD9, ie molecules expressed

tetraspanin CD9 interferes with the uptake of EVs by cancer cells

in opposite membranes, occurs. Indeed, our present data with diva‐

and primary MSCs as well as with the nuclear transfer of their cargo

lent Ab as mentioned above and the complete lack of EV endocytosis

proteins. The latter event is probably a direct consequence of the en‐

previously observed in melanoma cells in which CD9 was silenced in

docytosis inhibition of EVs. 23 Under these conditions, CD9 Fab could

both entities (cells and/or EVs), suggest it (Figure 1C). 23 It will be of

saturate the CD9 molecules located at the surface of cells and EVs

interest to investigate the CD9 cis/trans‐dimerization by co‐immu‐

and consequently interfere negatively with its function (Figure 6A;

noprecipitation using engineered CD9 proteins associated with cells

see below). The synergic impact of the pre‐incubation of cells and EVs

and EVs with distinct epitope tags.
Besides the exact molecular mechanism regulating the adhesion
of EVs to recipient cells and their internalization, it will be of interest
to determine whether other anti‐CD9 antibodies interfere with the
EV uptake and nuclear transfer of their cargo proteins, as observed
here with CD9 Fab derived from 5H9 Ab. The proper localization of
their respective epitope might be crucial to promote these effects
and it is conceivable that distinct CD9 Fab (or again other CD9 inter‐
acting partners) could potentially synergize their inhibitory effect.
Other tetraspanin proteins enriched in EVs such as CD81 should also
be evaluated in this respect.
The intercellular transfer of materials by cancer cell‐produced

F I G U R E 6 Schematic representation showing the negative
and positive impact of CD9 Fab and CD9 Ab, respectively, on
the endocytosis of CD9‐containing extracellular vesicles (EVs).
(A, B) CD9 Fab will saturate CD9 proteins present at the surface
of cells and EVs, hence interfere with its CD9 function. CD9 Fab
can impede the cis/trans‐dimerization of CD9, its oligomerization
and/or its interaction with other protein partners and block EV
endocytosis (red bar). In contrast, divalent CD9 Ab could cross‐link
CD9 proteins associated with host cells and EVs and consequently
stimulate the endocytosis on EVs (green arrow). In the latter
case, cis‐dimerization/oligomerization of CD9 might organize the
components (proteins and lipids) of plasma membrane and/or EV
membrane into a specific tetraspanin web (green segment), whose
constituents, notably potential adhesion proteins as illustrated
would somehow regulate the cell‐EV interaction and promote the
endocytosis of EVs

EVs played a significant role in the transformation of microenviron‐
ment, notably in the bone marrow, to favour metastasis and tumour
growth.7 Interfering locally with these mechanisms, particularly
the internalization of cancer cell‐derived EVs by MSCs, one of the
main targeted cellular constituents of tumour niche,58 could find a
cutting‐edge clinical application. MSCs have an important role in
co‐ordinating the tumour microenvironment. Transformed MSCs
produced growth factors favouring tumour growth and angiogene‐
sis, inhibited anti‐tumour immune responses and shaped the tumour
inflammatory environment.59-61 Thus, our data with MSCs exposed
to CD9 Fab might find new avenues to prevent the bone marrow
transformation. In addition to cancers, other diseases involving the
intercellular transfer of biomaterials mediated by EVs, such as neuro‐
degenerative diseases (eg, Parkinson's disease, Alzheimer's disease,
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amyotrophic lateral sclerosis), could benefit from this new potential
therapeutic approach.

62,63

Finally, our observations could benefit the areas of regenerative
medicine and tissue engineering. Here, the stimulation of EV endo‐
cytosis by specific divalent antibodies could favour tissue/organ re‐
pair.64 Myocardial regeneration might be a good example for such
intervention with MSCs as a promising source of donor cell EVs.65,66
Such approach could be an interesting alternative to stem cell‐based
therapy.
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